PD46-02 EXTERNAL VALIDATION OF A NOMOGRAM TO PREDICT BLEEDING INTERVENTIONS AFTER HIGH-GRADE RENAL TRAUMA
Jeremy B. Myers(University of Utah), Katie Glavin(University of Kansas Medical Center), Nima Baradaran(The Ohio State University Wexner Medical Center), Chirag Arya(Cooper University Hospital), Judith C. Hagedorn(Rice University), Michael E. Rezaee(Dartmouth–Hitchcock Medical Center), Rachel Sensenig(Cooper University Hospital), James Mercer, Douglas Rogers, Joel A. Gross, Alexander P. Nocera(University of Alabama at Birmingham), Angela P. Presson(University of California, Los Angeles), Bryan B. Voelzke, Clara M. Castillejo Becerra(Mayo Clinic), Rachel A. Moses(Dartmouth–Hitchcock Medical Center), J. Patrick Selph(Urology Associates), Elisa Wang, Chong Zhang, Shubham Gupta(Madurai Medical College), Sherry Wang(Pfizer (United States)), Raminder Nirula(University of Utah), Joshua A. Broghammer(University of Kansas Medical Center), Ryan Joyce
Cited by 0
Related Papers
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
|Nature Medicine|2020|399
Integrated Weighted Gene Co-expression Network Analysis with an Application to Chronic Fatigue Syndrome
|BMC Systems Biology|2008|213
Crizotinib in Patients With MET-Amplified NSCLC
|Journal of Thoracic Oncology|2021|171
Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT
|Journal of the American Heart Association|2018|118
Efficacy and safety of crizotinib in patients (pts) with advanced <i>MET</i> exon 14-altered non-small cell lung cancer (NSCLC).
|Journal of Clinical Oncology|2016|113